MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Drug Development Technology' source. Thu, 09 Feb 2012 01:31:30 +0100 http://www.medworm.com/index.php?rid=5669354&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsanacor-reports-safety-and-tolerability-results-of-an2728-ointment Anacor Pharmaceuticals has reported positive preliminary results from two safety studies of AN2728 ointment, 2%. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669354 Wed, 08 Feb 2012 00:00:00 +0100 5669354 http://www.medworm.com/index.php?rid=5669353&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsepicept-files-fast-track-status-for-amiket EpiCept Corporation has filed a fast track designation with the US Food and Drug Administration (FDA) for its AmiKet, used for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669353 Wed, 08 Feb 2012 00:00:00 +0100 5669353 http://www.medworm.com/index.php?rid=5669356&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsziopharm-oral-palifosfamide-gets-fda-ind-approval The US Food and Drug Administration (FDA) has accepted the investigational new drug application for Ziopharm Oncology's oral Palifosfamide (Zymafos or ZIO-201), which is used as a treatment for metastatic soft tissue sarcoma. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669356 Tue, 07 Feb 2012 00:00:00 +0100 5669356 http://www.medworm.com/index.php?rid=5669355&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscabozantinib-shows-efficacy-in-renal-cancer-patients Exelixis has reported the preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing Phase 1b trial of Cabozantinib. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669355 Tue, 07 Feb 2012 00:00:00 +0100 5669355 http://www.medworm.com/index.php?rid=5669359&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturemedical-cargo-theft-securing-the-supply-chain%2F With companies outsourcing clinical trials to emerging nations, medical cargo theft has become a major concern. Prior to Arena International's Clinical Trial Supply Europe, Elisabeth Fischer talks to Cathy Brown, process improvement manager within se… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669359 Mon, 06 Feb 2012 00:00:00 +0100 5669359 http://www.medworm.com/index.php?rid=5669358&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmerck-joins-threshold-to-co-develop-th-302-drug Merck and Threshold Pharmaceuticals have entered into a global agreement to jointly develop and commercialise Threshold Pharmaceuticals' hypoxia-targeted drug, TH-302, which is thought to be activated under tumour hypoxic conditions. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669358 Mon, 06 Feb 2012 00:00:00 +0100 5669358 http://www.medworm.com/index.php?rid=5669357&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsogx-427-plus-prednisone-found-effective-against-prostate-cancer OncoGenex Pharmaceuticals has announced the preliminary results from a Phase 2 study of its investigational compound OGX-427, designed for the treatment of chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (mCRPC). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5669357 Mon, 06 Feb 2012 00:00:00 +0100 5669357 http://www.medworm.com/index.php?rid=5661322&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsobd-drug-meets-phase-3-trial-primary-endpoint-sucampo-takeda Sucampo Pharmaceuticals (SPI) and Takeda Pharmaceuticals have announced the results from the Phase 3 clinical trial of lubiprostone as a treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those ta… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5661322 Fri, 03 Feb 2012 00:00:00 +0100 5661322 http://www.medworm.com/index.php?rid=5661321&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsipsen-reports-q4-and-full-year-2011-sales Ipsen, a global specialty-driven pharmaceutical company, has reported its fourth quarter and full year results with total sales exceeding €1.1bn in 2011. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5661321 Fri, 03 Feb 2012 00:00:00 +0100 5661321 http://www.medworm.com/index.php?rid=5651442&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeatureless-is-more-why-rare-disease-funding-is-on-the-up%2F Despite reductions in R&D spending, clinical trials for rare diseases are going full steam ahead. Elly Earls speaks to Alastair Kent of Genetic Alliance UK, Tim Cote of the National Organization for Rare Disorders (NORD) and Dr Steve Groft of the Off… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651442 Thu, 02 Feb 2012 00:00:00 +0100 5651442 http://www.medworm.com/index.php?rid=5651441&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmdv3100-shows-efficacy-against-prostate-cancer Medivation and Astellas Pharma have announced the positive results from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651441 Thu, 02 Feb 2012 00:00:00 +0100 5651441 http://www.medworm.com/index.php?rid=5651440&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsnovartis-glivec-wins-extended-fda-approval-for-three-year-treatment The Novartis Glivec (imatinib) label has received an extended approval by the US Food and Drug Administration (FDA) to recommend 36 months of treatment for adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651440 Thu, 02 Feb 2012 00:00:00 +0100 5651440 http://www.medworm.com/index.php?rid=5651445&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsboehringer-eli-lilly-diabetes-drug-wins-fda-nod Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced that the US Food and Drug Administration (FDA) has approved Jentadueto (linagliptin / metformin hydrochloride) tablets, used for treating adults with type 2 diabetes. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651445 Wed, 01 Feb 2012 00:00:00 +0100 5651445 http://www.medworm.com/index.php?rid=5651444&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fprovenge-for-the-treatment-of-advanced-prostate-cancer%2F Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651444 Wed, 01 Feb 2012 00:00:00 +0100 5651444 http://www.medworm.com/index.php?rid=5651443&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsargos-reports-ags-003-combination-therapy-trial-data Argos Therapeutics' Arcelis immunotherapy, AGS-003, in combination with sunitinib has showed a correlation between anti-tumour memory T cell responses and overall survival in Phase 2 study in patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651443 Wed, 01 Feb 2012 00:00:00 +0100 5651443 http://www.medworm.com/index.php?rid=5651447&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-clears-pfizer-inlyta-for-kidney-cancer The US Food and Drug Administration (FDA) has approved Pfizer's Inlyta (axitinib), a kinase inhibitor, intended for treating patients with advanced renal cell carcinoma (RCC) following failure of one prior systemic therapy. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651447 Tue, 31 Jan 2012 00:00:00 +0100 5651447 http://www.medworm.com/index.php?rid=5651446&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsallos-therapeutics-reports-interim-data-of-folotyn-combination-therapy Allos Therapeutics has announced the interim results from the ongoing Phase 1 combination study of Folotyn (pralatrexate injection) and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651446 Tue, 31 Jan 2012 00:00:00 +0100 5651446 http://www.medworm.com/index.php?rid=5651449&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmillennium-announces-phase-i-trial-data-of-adcetris Millennium, part of the Takeda Group, has announced the interim results from a Phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination with or sequentially with chemotherapy to treat newly diagnosed systemic anaplastic la… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651449 Mon, 30 Jan 2012 00:00:00 +0100 5651449 http://www.medworm.com/index.php?rid=5651448&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsamylin-alkermes-diabetes-drug-wins-fda-approval Amylin Pharmaceuticals and Alkermes have announced that the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651448 Mon, 30 Jan 2012 00:00:00 +0100 5651448 http://www.medworm.com/index.php?rid=5651450&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbiogen-idec-elan-begins-multiple-sclerosis-drug-study Biogen Idec and Elan Corporation are conducting a global Phase 3b study, designed to evaluate the effectiveness of Tysabri as a treatment for secondary-progressive multiple sclerosis (SPMS). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5651450 Fri, 27 Jan 2012 00:00:00 +0100 5651450 http://www.medworm.com/index.php?rid=5639955&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewschimerix-reports-phase-2-trial-data-of-cmx001 Chimerix, a biotechnology company developing novel antiviral therapeutics, has announced the final data from Phase II study 201 evaluating CMX001 for the prevention of cytomegalovirus (CMV). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5639955 Fri, 27 Jan 2012 00:00:00 +0100 5639955 http://www.medworm.com/index.php?rid=5631132&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmerck-serono-introduces-rebif-in-uk Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has introduced Rebif (interferon beta-1a) in the UK to treat people who have experienced clinically isolated syndrome (CIS), an early sign of multiple sclerosis (MS). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631132 Thu, 26 Jan 2012 00:00:00 +0100 5631132 http://www.medworm.com/index.php?rid=5631131&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsadvaxis-reports-safety-and-survival-data-of-cancer-drug Advaxis has reported the preliminary data on the safety and clinical benefit of ADXS-HPV with or without cisplatin in Indian women with recurrent / refractory cervical cancer who have failed cytotoxic therapy from an ongoing randomised Phase II trial… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631131 Thu, 26 Jan 2012 00:00:00 +0100 5631131 http://www.medworm.com/index.php?rid=5631133&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fsterilisation%2Fpriorclave-autoclave%2Fpressvacuum-autoclave-stand-off-legs.html Priorclave's Compact C40 vacuum autoclave is the first priorclave to become available with stand-off legs, providing easy access beneath the steam steriliser for cleaning and disinfection of laboratory work surfaces. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631133 Wed, 25 Jan 2012 15:38:00 +0100 5631133 http://www.medworm.com/index.php?rid=5631136&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsventirx-announces-positive-tlr8-agonist-preclinical-data VentiRx Pharmaceuticals has announced preclinical data demonstrating that VTX-2337, the company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631136 Wed, 25 Jan 2012 00:00:00 +0100 5631136 http://www.medworm.com/index.php?rid=5631135&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsgilead-begins-phase-2-study-of-hiv-drug Gilead Sciences has begun a Phase II clinical trial of its GS-7340 drug, used as a treatment for HIV-1 infection in treatment-naive adults. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631135 Wed, 25 Jan 2012 00:00:00 +0100 5631135 http://www.medworm.com/index.php?rid=5631134&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturepharma-technology-focus-issue-9%2F In this issue we investigate how rapidly evolving drug delivery methods are helping to make medicines more effective. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631134 Wed, 25 Jan 2012 00:00:00 +0100 5631134 http://www.medworm.com/index.php?rid=5631138&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsimmunomedics-reports-encouraging-data-from-phase-ibii-pancreatic-cancer-study Immunomedics has reported data from Phase Ib/II study of Yttrium-90-labelled clivatuzumab tetraxetan and gemcitabine in advanced pancreatic cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631138 Tue, 24 Jan 2012 00:00:00 +0100 5631138 http://www.medworm.com/index.php?rid=5631137&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsspectrum-announces-positive-results-from-zevalin-study Spectrum Pharmaceuticals has reported results from a randomised study comparing Zevalin (ibritumomab tiuxetan) injection for intravenous use plus high-dose BEAM chemotherapy with BEAM chemotherapy alone. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5631137 Tue, 24 Jan 2012 00:00:00 +0100 5631137 http://www.medworm.com/index.php?rid=5621684&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturegoing-with-the-flow-continuous-manufacturing%2F As manufacturing models embrace process analytical technology, big pharma has to reassess the way it produces drugs. Elisabeth Fischer profiles the opportunities and stumbling blocks of continuous manufacturing and finds out how it will revolutionise… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5621684 Mon, 23 Jan 2012 00:00:00 +0100 5621684 http://www.medworm.com/index.php?rid=5621683&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscabozantinib-found-to-treat-patients-with-hepatocellular-carcinoma Exelixis's cabozantinib has demonstrated positive effects in treating hepatocellular carcinoma (HCC) cohort patients during the ongoing Phase 2 randomized discontinuation trial (RDT). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5621683 Mon, 23 Jan 2012 00:00:00 +0100 5621683 http://www.medworm.com/index.php?rid=5621682&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewstesetaxel-shows-efficacy-against-gastric-cancer-in-study Genta Incorporated has announced positive results from the Phase 2b confirmatory clinical trial, designed to evaluate tesetaxel in treating patients with advanced gastric cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5621682 Mon, 23 Jan 2012 00:00:00 +0100 5621682 http://www.medworm.com/index.php?rid=5612180&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsadeona-begins-phase-ii-study-of-multiple-sclerosis-drug Adeona Pharmaceuticals, a developer of synthetic DNA-based therapeutics, has commenced the Phase II clinical trial of its Trimesta drug, designed to treat cognitive dysfunction in multiple sclerosis (MS). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612180 Fri, 20 Jan 2012 00:00:00 +0100 5612180 http://www.medworm.com/index.php?rid=5612179&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbristol-myers-reports-phase-ii-data-of-daa-therapy-against-hcv Bristol-Myers Squibb has reported the Phase II clinical trial results of direct-acting antiviral (DAA) therapy in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612179 Fri, 20 Jan 2012 00:00:00 +0100 5612179 http://www.medworm.com/index.php?rid=5612182&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsregorafenib-found-to-treat-colorectal-cancer-bayer-reports Bayer HealthCare's Regorafenib (BAY 73-4506) drug has demonstrated the efficacy in Phase 3 Colorectal cancer treated with Regorafenib or placebo after failure of standard therapy (CORRECT) trial. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612182 Thu, 19 Jan 2012 00:00:00 +0100 5612182 http://www.medworm.com/index.php?rid=5612181&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmedia-soft-develops-new-pharma-crm-solution Media-Soft, a pharmacentric company, has developed new flagship product Sales Vision Android, an offline / online Android-based pharma CRM and SFE tool for pharmaceuticals. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612181 Thu, 19 Jan 2012 00:00:00 +0100 5612181 http://www.medworm.com/index.php?rid=5612186&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspergamum-doses-first-patient-in-phase-ii-trial-of-dpk-060 Sweden-based Pergamum has dosed the first patient in a randomised Phase II study of DPK-060, designed for the treatment of patients with external otitis (swimmers ear). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612186 Wed, 18 Jan 2012 00:00:00 +0100 5612186 http://www.medworm.com/index.php?rid=5612185&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fvyndaqel-tafamidis-for-the-treatment-of-transthyretin-familial-amyloid-polyneuropathy%2F Vyndaqel (tafamidis) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612185 Wed, 18 Jan 2012 00:00:00 +0100 5612185 http://www.medworm.com/index.php?rid=5612184&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeatureinternational-drug-discovery-breaking-new-ground-at-dubai-2012%2F The fourth International Conference on Drug Discovery and Therapy provides a unique platform for collaboration. Drugdevelopment-technology.com previews the big issues and breakthroughs that will be hot on the lips of the world's pre-eminent pharmaceu… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612184 Wed, 18 Jan 2012 00:00:00 +0100 5612184 http://www.medworm.com/index.php?rid=5612183&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsvivus-avanafil-shows-efficacy-against-erectile-dysfunction Vivus has reported the results from its Phase III Revive study investigating the safety and efficacy of an investigational drug Avanafil, used for the treatment of erectile dysfunction (ED). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5612183 Wed, 18 Jan 2012 00:00:00 +0100 5612183 http://www.medworm.com/index.php?rid=5600088&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewslundbeck-introduces-new-treatment-for-depressive-disorder-in-uk Lundbeck, an international pharmaceutical company, has announced that Sycrest (asenapine) is being launched in the UK for treating moderate to severe manic episodes associated with bipolar I disorder in adults. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5600088 Tue, 17 Jan 2012 00:00:00 +0100 5600088 http://www.medworm.com/index.php?rid=5600087&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsganetespib-with-docetaxel-found-effective-against-lung-cancer-synta-reports Synta Pharmaceuticals has reported the favourable safety profile of Ganetespib, a non-ansamycin inhibitor of Hsp90, in multiple non-small cell lung cancer (NSCLC) xenograft models. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5600087 Tue, 17 Jan 2012 00:00:00 +0100 5600087 http://www.medworm.com/index.php?rid=5600090&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsnovalix-teijin-pharma-strike-drug-discovery-alliance NovAliX SAS has entered into a multitarget integrated drug discovery collaboration with Tokyo-based Teijin Pharma to develop novel drug candidates against multiple targets across different therapeutic areas. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5600090 Mon, 16 Jan 2012 00:00:00 +0100 5600090 http://www.medworm.com/index.php?rid=5600089&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsventrus-iferanserin-ointment-found-to-treat-hemorrhoids Ventrus BioSciences has announced the results from the Phase IIb study of Iferanserin ointment (VEN 309), its novel investigational drug for the treatment of symptomatic haemorrhoids. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5600089 Mon, 16 Jan 2012 00:00:00 +0100 5600089 http://www.medworm.com/index.php?rid=5586049&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbbr-concludes-preclinical-trials-of-obesity-compound Bridge Bioresearch (BBR) has completed the preclinical efficacy and safety trials of 2hydroxyoleic acid (2OHOA), a novel treatment for obesity and other metabolic disorders. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586049 Fri, 13 Jan 2012 00:00:00 +0100 5586049 http://www.medworm.com/index.php?rid=5586048&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fexparel-for-postsurgical-pain-relief%2F Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical pain. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586048 Fri, 13 Jan 2012 00:00:00 +0100 5586048 http://www.medworm.com/index.php?rid=5586047&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscsl-behring-begins-phase-iiiii-hemophilia-study CSL Behring has initiated a global phase II/III, multi-centre study, designed to investigate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586047 Fri, 13 Jan 2012 00:00:00 +0100 5586047 http://www.medworm.com/index.php?rid=5586051&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspolaris-doses-first-patient-in-prostate-cancer-drug-phase-1-trial Polaris Group has dosed the first prostate cancer patient in its Phase 1 clinical trial investigating the cancer therapeutic pegylated arginine deiminase (ADI-PEG 20) in combination with docetaxel. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586051 Thu, 12 Jan 2012 00:00:00 +0100 5586051 http://www.medworm.com/index.php?rid=5586050&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsspherix-concludes-spx-106-drug-toxicology-study Spherix, a developer of proprietary therapeutic products for the treatment of diabetes, metabolic syndrome and atherosclerosis, has successfully completed the 28-day rat toxicology study of its drug candidate SPX-106. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586050 Thu, 12 Jan 2012 00:00:00 +0100 5586050 http://www.medworm.com/index.php?rid=5586053&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscynapsus-reports-positive-results-from-parkinsons-drug-trial Cynapsus Therapeutics, a Canada-based speciality pharmaceutical company, has reported positive top-line data from its human volunteer pilot proof-of-concept Phase I study of APL 130277 to treat the symptoms of Parkinson's disease. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586053 Wed, 11 Jan 2012 00:00:00 +0100 5586053 http://www.medworm.com/index.php?rid=5586052&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewslx4211-combination-therapy-found-to-treat-type-2-diabetes Lexicon Pharmaceuticals has announced the top-line results from the first clinical study evaluating the combined effects of LX4211, a sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with dipeptidyl peptidase 4 (DPP-4) inhibitor sitagl… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586052 Wed, 11 Jan 2012 00:00:00 +0100 5586052 http://www.medworm.com/index.php?rid=5586055&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsidenix-reports-positive-interim-trial-data-for-hepatitis-c-drug Idenix Pharmaceuticals has reported the positive interim data from a 12-week Phase IIb clinical trial of IDX184, a drug candidate for the treatment for hepatitis C virus infection. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586055 Tue, 10 Jan 2012 00:00:00 +0100 5586055 http://www.medworm.com/index.php?rid=5586054&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbiocryst-reports-long-term-results-of-bcx4208-therapy BioCryst Pharmaceuticals has reported positive results from the extension phase of its randomised Phase 2b study of BCX4208 added to allopurinol in patients with gout. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586054 Tue, 10 Jan 2012 00:00:00 +0100 5586054 http://www.medworm.com/index.php?rid=5586057&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewshypercholesterolaemia-drug-lomitapide-shows-efficacy-in-trial Aegerion Pharmaceuticals drug candidate Lomitapide has demonstrated long-term safety and efficacy results in a 78-week Phase III clinical trial. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586057 Mon, 09 Jan 2012 00:00:00 +0100 5586057 http://www.medworm.com/index.php?rid=5586056&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewseyegate-enrols-first-patient-in-phase-iii-anterior-uveitis-study EyeGate Pharma has enrolled the first patient in a Phase III pivotal study of its EGP-437 product, a late-stage asset with multiple indications for inflammatory ocular indications used to treat anterior uveitis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586056 Mon, 09 Jan 2012 00:00:00 +0100 5586056 http://www.medworm.com/index.php?rid=5586059&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbaxter-doses-first-patient-in-bax-855-drug-study Baxter International has begun dosing the first patients in a Phase I clinical trial of investigational candidate BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586059 Fri, 06 Jan 2012 00:00:00 +0100 5586059 http://www.medworm.com/index.php?rid=5586058&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturesnapshot-the-market-for-neuropathic-pain-therapeutics%2F As conditions such as diabetes become more common, the market for new pain drugs is becoming increasingly competitive. Using detailed GlobalData research this snapshot examines the market forces behind a sector expected to grow by 9.6% from $4.8bn in… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586058 Fri, 06 Jan 2012 00:00:00 +0100 5586058 http://www.medworm.com/index.php?rid=5573500&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsista-begins-beposone-nasal-spray-study Ista Pharmaceuticals' Beposone nasal spray has entered into a Phase II clinical study in conjugation with bepotastine besilate and a steroid for the treatment of the symptoms associated with seasonal allergic rhinitis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5573500 Fri, 06 Jan 2012 00:00:00 +0100 5573500 http://www.medworm.com/index.php?rid=5586060&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsachillion-hcv-drug-receives-fda-fast-track-status The US Food and Drug Administration (FDA) has granted fast track designation to Achillion Pharmaceuticals' ACH-1625 drug, which is being evaluated in a Phase II clinical trial as a treatment for chronic hepatitis C virus (HCV). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5586060 Thu, 05 Jan 2012 00:00:00 +0100 5586060 http://www.medworm.com/index.php?rid=5562857&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsrepros-doses-patient-in-low-dose-oral-proellex-trial Repros Therapeutics has completed patient dosing in its Phase II low-dose trial of oral Proellex, intended for the treatment of symptoms of uterine fibroids and endometriosis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5562857 Thu, 05 Jan 2012 00:00:00 +0100 5562857 http://www.medworm.com/index.php?rid=5562859&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsccs-strikes-license-agreement-with-emd-millipore Cell Culture Service has entered into a general license agreement with EMD Millipore, a division of Merck. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5562859 Wed, 04 Jan 2012 00:00:00 +0100 5562859 http://www.medworm.com/index.php?rid=5562858&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-committee-to-review-resubmitted-nda-for-pixantrone Cell Therapeutics has announced that the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee will review the company's resubmitted New Drug Application (NDA) for Pixantrone on 9 February 2012. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5562858 Wed, 04 Jan 2012 00:00:00 +0100 5562858 http://www.medworm.com/index.php?rid=5562861&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsagile-completes-phase-iii-study-of-hormonal-contraceptive-patch Agile Therapeutics has concluded the final Phase III clinical trial of AG200-15, the company's hormonal contraceptive patch containing ethinyl estradiol in combination with levonorgestrel. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5562861 Tue, 03 Jan 2012 00:00:00 +0100 5562861 http://www.medworm.com/index.php?rid=5562860&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspfizer-pneumonia-vaccine-receives-fda-clearance The US Food and Drug Administration (FDA) has approved the extended use of Pfizer's pneumococcal conjugate vaccine- Prevnar 13 as a single-dose treatment for pneumonia in adults. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5562860 Tue, 03 Jan 2012 00:00:00 +0100 5562860 http://www.medworm.com/index.php?rid=5539839&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsxoma-commences-gevokizumab-phase-2-study Xoma has initiated patient dosing in its Phase II proof-of-concept study, designed to investigate the efficacy and safety of Gevokizumab (XOMA 052), an inhibitor of interleukin-1 beta, used to treat inflammatory lesions seen in moderate to severe acn… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5539839 Fri, 23 Dec 2011 00:00:00 +0100 5539839 http://www.medworm.com/index.php?rid=5539838&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsseasons-greetings We will be taking a short break over the holiday season. Our daily news service will return in full on 3 January. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5539838 Fri, 23 Dec 2011 00:00:00 +0100 5539838 http://www.medworm.com/index.php?rid=5539841&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsjennerex-treats-first-patient-in-phase-2a-study-of-cancer-drug Jennerex, a private clinical-stage biotherapeutics company, has treated the first patient in a Phase IIa clinical trial of JX-594, as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5539841 Thu, 22 Dec 2011 00:00:00 +0100 5539841 http://www.medworm.com/index.php?rid=5539840&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-clears-takeda-edarbyclor-fixed-dose-combination-regimen The US Food and Drug Administration (FDA) has approved Takeda Pharmaceutical's Edarbyclor as a treatment for hypertension in adults. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5539840 Thu, 22 Dec 2011 00:00:00 +0100 5539840 http://www.medworm.com/index.php?rid=5527843&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsexparel-shows-efficacy-against-pain-management Pacira Pharmaceuticals has reported the results from a placebo-controlled, pivotal Phase III trial of Exparel (bupivacaine liposome injectable suspension), a non-opioid local analgesic for administration into a surgical site. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527843 Wed, 21 Dec 2011 00:00:00 +0100 5527843 http://www.medworm.com/index.php?rid=5527842&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsnovartis-concludes-altitude-study-with-rasilez-tekturna Novartis has decided to conclude the Altitude study with Rasilez/Tekturna (aliskiren), on the recommendation of the independent data monitoring committee overseeing the trial. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527842 Wed, 21 Dec 2011 00:00:00 +0100 5527842 http://www.medworm.com/index.php?rid=5527846&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fcontract_research%2Fkemwell%2F Kemwell is a full service provider and a 100% customer-oriented company with extensive expertise in contract manufacturing and development services for pharmaceutical products. With Kemwell you will ... (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527846 Tue, 20 Dec 2011 00:00:00 +0100 5527846 http://www.medworm.com/index.php?rid=5527845&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsraptor-pharmaceutical-agrees-rp104-research-deal Raptor Pharmaceutical has entered into a cooperative research and development agreement with the National Institute of Diabetes and Digestive and Kidney Diseases to conduct a Phase IIb clinical trial of drug candidate RP104. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527845 Tue, 20 Dec 2011 00:00:00 +0100 5527845 http://www.medworm.com/index.php?rid=5527844&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsgalapagos-glpg0778-shows-selective-effects-on-biomarkers-in-phase-i-study Belgium-based biotechnology company Galapagos has announced that its investigational medicine GLPG0778, a kinase target GT623 inhibitor, has demonstrated selective effects on a biomarker in a Phase I proof-of-mechanism study in healthy volunteers. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527844 Tue, 20 Dec 2011 00:00:00 +0100 5527844 http://www.medworm.com/index.php?rid=5527847&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturefuture-oncology-the-path-to-personalised-medicine%2F Could the genetic screening of tumour tissues push oncology into the era of personalised patient cancer treatment? Elisabeth Fischer talks to the researchers of the Stratified Cancer Programme in the UK and finds out how looking at cancer mutations c… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5527847 Mon, 19 Dec 2011 00:00:00 +0100 5527847 http://www.medworm.com/index.php?rid=5516838&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fdownloads%2Fwhitepapers%2Fclinical_development%2Ffiletargeting-leukocyte-recruitment%2F The recruitment of leukocytes into sites of inflammation is crucial for the pathogenesis of many inflammatory disorders, making it an attractive target for anti-inflammatory drug discovery. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516838 Mon, 19 Dec 2011 00:00:00 +0100 5516838 http://www.medworm.com/index.php?rid=5516837&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-clears-vertex-kalydeco-nda The US Food and Drug Administration (FDA) has granted Vertex Pharmaceuticals' New Drug Application (NDA) and its request for a six-month Priority Review of its Kalydeco (ivacaftor, VX-770) drug, used to treat people with cystic fibrosis (CF). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516837 Mon, 19 Dec 2011 00:00:00 +0100 5516837 http://www.medworm.com/index.php?rid=5516836&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspfizer-lyrica-capsules-meet-co-primary-endpoints Pfizer has announced that its Lyrica (pregabalin) capsules have met each of its three co-primary endpoints in the Phase III study evaluating it in patients with restless legs syndrome. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516836 Mon, 19 Dec 2011 00:00:00 +0100 5516836 http://www.medworm.com/index.php?rid=5516835&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fsterilisation%2Fpriorclave-autoclave%2Fpresspriorclave-london-vet-show.html During the recent London Vet Show the autoclave supplied by Priorclave and featured on the Southwest Medical stand surprised visitors with its compact outward physical appearance and the larger than average steam sterilisation chamber. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516835 Mon, 19 Dec 2011 00:00:00 +0100 5516835 http://www.medworm.com/index.php?rid=5516834&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fsterilisation%2Fpriorclave-autoclave%2Fpresspriorclave-york-university.html York University will soon be taking delivery of a number of priorclaves for use in the biology department's teaching laboratories and associated central wash-up and sterilising facilities. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516834 Mon, 19 Dec 2011 00:00:00 +0100 5516834 http://www.medworm.com/index.php?rid=5516839&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbiosante-reports-libigel-efficacy-trials-data BioSante Pharmaceuticals has announced the top-line results from its two pivotal Phase III efficacy trials of LibiGel (testosterone gel), used for the treatment of postmenopausal women who suffer from female sexual dysfunction, specifically hypoactiv… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5516839 Fri, 16 Dec 2011 00:00:00 +0100 5516839 http://www.medworm.com/index.php?rid=5507473&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsnovartis-multiple-sclerosis-drug-shows-positive-clinical-results A Phase III study conducted by Novartis has revealed that Gilenya (fingolimod) has demonstrated a 48% reduction in annualised relapse rates in patients with relapsing-remitting multiple sclerosis after 24 months, compared with a placebo. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507473 Fri, 16 Dec 2011 00:00:00 +0100 5507473 http://www.medworm.com/index.php?rid=5507476&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsth-302-shows-efficacy-against-leukemia-threshold-reports Threshold Pharmaceuticals' TH-302 drug has produced promising clinical trial results in the Phase I study performed at MD Anderson's Cancer Center in Houston, US, for treating patients with advanced leukemias. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507476 Thu, 15 Dec 2011 00:00:00 +0100 5507476 http://www.medworm.com/index.php?rid=5507475&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmabthera-combined-with-chemotherapy-found-to-treat-lymphoma-patients A Cancer Research UK funded UK Phase III trial of MabThera, combined with chemotherapy in the treatment of newly diagnosed patients with Mantle Cell Lymphoma (MCL), has shown considerably increased survival by at least eight months. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507475 Thu, 15 Dec 2011 00:00:00 +0100 5507475 http://www.medworm.com/index.php?rid=5507474&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fgenomics%2Ftissue-solutions%2Fpressoraclebio-histologix-collaboration.html A new partnership provides tissue to data biomarker solutions. 'Our expertise provides your solutions' is the new motto being used as part of a unique and exciting partnership between three independent CROs in the life science sector. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507474 Thu, 15 Dec 2011 00:00:00 +0100 5507474 http://www.medworm.com/index.php?rid=5507479&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-grants-fast-track-status-to-celladon-mydicar-drug The US Food and Drug Administration (FDA) has granted fast-track designation of Celladon's investigational product candidate Mydicar, which is designed to treat advanced heart failure. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507479 Wed, 14 Dec 2011 00:00:00 +0100 5507479 http://www.medworm.com/index.php?rid=5507478&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturepharma-technology-focus-issue-8%2F In this issue we look at securing supply chains and optimising logistics. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507478 Wed, 14 Dec 2011 00:00:00 +0100 5507478 http://www.medworm.com/index.php?rid=5507477&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsnovartis-reports-phase-iii-study-results-of-inc424 Novartis has presented the supplementary results from two pivotal Phase III trials investigating its INC424 (ruxolitinib) drug, a Janus kinase (JAK) inhibitor that is used to treat patients with myelofibrosis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5507477 Wed, 14 Dec 2011 00:00:00 +0100 5507477 http://www.medworm.com/index.php?rid=5496954&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsabbott-joins-reata-to-develop-oral-antioxidant-inflammation-modulators Abbott has signed a collaboration agreement with Reata Pharmaceuticals to develop and commercialise Reata's portfolio of second-generation oral antioxidant inflammation modulators. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496954 Tue, 13 Dec 2011 00:00:00 +0100 5496954 http://www.medworm.com/index.php?rid=5496953&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsgenmab-reports-encouraging-preliminary-data-from-phase-iii-multiple-myeloma-study Genmab has reported encouraging preliminary safety and efficacy data from the first Phase I/II clinical study of daratumumab (HuMax-CD38) in multiple myeloma. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496953 Tue, 13 Dec 2011 00:00:00 +0100 5496953 http://www.medworm.com/index.php?rid=5496952&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fgenomics%2Fbiognosys%2Fpresscommercial-mrm-software.html Setting up scheduled multiplexed MRM experiments and processing MRM signals is a challenge in proteomics research. Biognosys' proprietary software mQuest / mProphet, the RT-Kit and MRMbase assays resolve these issues (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496952 Tue, 13 Dec 2011 00:00:00 +0100 5496952 http://www.medworm.com/index.php?rid=5496951&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fanacetrapib---treatment-for-atherosclerosis%2F Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of atherosclerosis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496951 Tue, 13 Dec 2011 00:00:00 +0100 5496951 http://www.medworm.com/index.php?rid=5496956&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscelgene-reports-encouraging-data-from-cll-investigational-study Celgene International has announced interim results of CLL-009 followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who received at least one prior therapy. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496956 Mon, 12 Dec 2011 00:00:00 +0100 5496956 http://www.medworm.com/index.php?rid=5496955&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsarhalofenate-combination-therapy-found-to-treat-gout Metabolex has announced the positive results from its clinical study of Arhalofenate in combination with febuxostat (Uloric), used to treat patients with hyperuricemia and gout. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496955 Mon, 12 Dec 2011 00:00:00 +0100 5496955 http://www.medworm.com/index.php?rid=5496957&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsenzon-reports-positive-phase-ii-data-of-cancer-drug Enzon Pharmaceuticals' PEG-SN38 (EZN-2208) has demonstrated positive results in a Phase II open-label study involving patients previously treated with metastatic breast cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496957 Fri, 09 Dec 2011 00:00:00 +0100 5496957 http://www.medworm.com/index.php?rid=5489123&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsmolecular-partners-janssen-enter-research-collaboration-deal Molecular Partners has signed a strategic research collaboration with Janssen Biotech, for designed ankyrin repeat protein (DARPin) products for the treatment of immunological diseases. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5489123 Fri, 09 Dec 2011 00:00:00 +0100 5489123 http://www.medworm.com/index.php?rid=5489126&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspharmathene-presents-anthrax-anti-toxin-study-results PharmAthene has announced the results of a Phase I clinical study of Valortim, a fully human monoclonal antibody, used as both post-exposure prophylaxis and therapeutic treatment for anthrax infection. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5489126 Thu, 08 Dec 2011 00:00:00 +0100 5489126 http://www.medworm.com/index.php?rid=5489125&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsgenentech-reports-positive-results-of-cancer-drug Genentech, a member of the Roche Group, has presented the positive results from the first randomised Phase III study, designed to investigate HER2-targeted medicine Pertuzumab. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5489125 Thu, 08 Dec 2011 00:00:00 +0100 5489125 http://www.medworm.com/index.php?rid=5489124&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeatureenhancing-bioavailability%2F Poor solubility can be critical for otherwise life-saving drugs, but new information could herald a welcome solution. Elly Earls speaks to John Comer of Sirius Analytical and Dr Woei Ping Cheng of the University of Hertfordshire about the latest deve… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5489124 Thu, 08 Dec 2011 00:00:00 +0100 5489124 http://www.medworm.com/index.php?rid=5496958&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fcontract_research%2Fikfe%2F1313848096001.html As a German-based full-service contract research organisation, ikfe CRO provides a wide range of services to pharmaceutical and biotechnology companies across the world. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5496958 Wed, 07 Dec 2011 15:38:08 +0100 5496958 http://www.medworm.com/index.php?rid=5478918&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsperegrine-bavituximab-therapy-shows-efficacy-against-nsclc Peregrine Pharmaceuticals' Bavituximab, in combination with carboplatin and paclitaxel, has demonstrated 50% improvement in overall tumour response rates (ORR) in a Phase II trial evaluating non-small cell lung cancer (NSCLC) patients. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478918 Wed, 07 Dec 2011 00:00:00 +0100 5478918 http://www.medworm.com/index.php?rid=5478917&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fcontract_research%2Fikfe%2F ikfe CRO provides a wide range of services to pharmaceutical and biotechnology companies across the world. As a German-based full service contract research organisation, our pharmaceutical product de... (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478917 Wed, 07 Dec 2011 00:00:00 +0100 5478917 http://www.medworm.com/index.php?rid=5478916&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewslixisenatide-combination-therapy-found-to-treat-type-2-diabetes-sanofi-reports Sanofi-aventis has presented the positive top-line results from a Phase III study, GetGoal Duo 1, designed to investigate the efficacy and safety of lixisenatide (Lyxumia) in combination with Lantus (insulin glargine), for the treatment of patients w… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478916 Wed, 07 Dec 2011 00:00:00 +0100 5478916 http://www.medworm.com/index.php?rid=5478920&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsachillion-ach-2928-drug-shows-efficacy-against-chronic-hepatitis-c The randomised, double-blind, placebo-controlled Phase Ia/Ib clinical trial is intended to evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2928. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478920 Tue, 06 Dec 2011 00:00:00 +0100 5478920 http://www.medworm.com/index.php?rid=5478919&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewseylea-injection-found-to-improve-visual-acuity-in-wet-amd-patients Regeneron Pharmaceuticals and Bayer HealthCare have announced that in an integrated analysis of two parallel Phase III studies, Eylea (aflibercept) injection has shown improvements in visual acuity at 96 weeks in patients with the neovascular (wet) f… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478919 Tue, 06 Dec 2011 00:00:00 +0100 5478919 http://www.medworm.com/index.php?rid=5489127&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsamicus-treats-first-patient-in-at2220-study Amicus Therapeutics, a biopharmaceutical company that develops therapies for rare diseases, has infused the first patient in an Phase II drug-drug interaction study of AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy alglucosi… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5489127 Mon, 05 Dec 2011 00:00:00 +0100 5489127 http://www.medworm.com/index.php?rid=5478923&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbristol-myers-squibb-and-tibotec-to-collaborate-on-daclatasvir-trial Bristol-Myers Squibb has signed a clinical collaboration agreement with Medivir development partner Tibotec Pharmaceuticals for Phase II combination study in patients with chronic hepatitis C virus. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478923 Mon, 05 Dec 2011 00:00:00 +0100 5478923 http://www.medworm.com/index.php?rid=5478922&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fivacaftor---treatment-for-cystic-fibrosis%2F Ivacaftor (VX-770) is a cystic fibrosis transmembrance conductor regulator (CFTR) potentiator indicated for the treatment of Cystic Fibrosis (CF). (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478922 Mon, 05 Dec 2011 00:00:00 +0100 5478922 http://www.medworm.com/index.php?rid=5478921&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fcontract_research%2Faibio-tech%2Fpressaibiotech-assists-eusa-pharma.html AIBioTech is pleased to announce the successful completion of an assay validation and sample analysis program which was a critical component of EUSA Pharma's Biologics License Application for its Erwinaze™ (asparaginase Erwinia chrysanthemi) drug pro… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5478921 Mon, 05 Dec 2011 00:00:00 +0100 5478921 http://www.medworm.com/index.php?rid=5470653&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsboehringer-and-aveo-enter-into-manufacturing-deal-for-ficlatuzumab Aveo Pharmaceuticals has signed a manufacturing agreement with Boehringer Ingelheim for large-scale process development and clinical manufacturing of ficlatuzumab (AV-299), used to treat patients with non-small cell lung cancer. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5470653 Fri, 02 Dec 2011 00:00:00 +0100 5470653 http://www.medworm.com/index.php?rid=5470652&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewssantarus-uceris-tablet-found-to-treat-ulcerative-colitis US-based specialty biopharmaceutical company, Santarus, has reported the clinical data from an open-label study, designed to investigate the efficacy and safety of eight weeks of treatment with the investigational drug, Uceris (budesonide) 9 mg table… (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5470652 Fri, 02 Dec 2011 00:00:00 +0100 5470652 http://www.medworm.com/index.php?rid=5460632&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsroche-to-present-pertuzumab-combination-therapy-study-results Switzerland-based biotech company Roche will present the study results of its investigational medicine, Pertuzumab, in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 6-10 December 2011. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460632 Thu, 01 Dec 2011 00:00:00 +0100 5460632 http://www.medworm.com/index.php?rid=5460631&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscytokinetics-reports-positive-study-results-of-ck-2017357-drug Cytokinetics' CK-2017357 drug has met all primary endpoints in the first cohort of an ongoing Phase II clinical trial in patients with amyotrophic lateral sclerosis. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460631 Thu, 01 Dec 2011 00:00:00 +0100 5460631 http://www.medworm.com/index.php?rid=5460634&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewskomboglyze-combination-pill-receives-european-marketing-approval AstraZeneca and Bristol-Myers Squibb have announced that the European Commission has granted marketing approval for Komboglyze, used to treat adult patients with type 2 diabetes mellitus. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460634 Wed, 30 Nov 2011 00:00:00 +0100 5460634 http://www.medworm.com/index.php?rid=5460633&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewseuropean-commission-clears-novartis-rasilez-based-triple-combination-pill The European Commission has approved Novartis Pharmaceuticals' Rasitrio, a Rasilez-based triple combination pill of aliskiren, amlodipine and hydrochlorothiazide that is used as a substitution therapy for patients with high blood pressure. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460633 Wed, 30 Nov 2011 00:00:00 +0100 5460633 http://www.medworm.com/index.php?rid=5460636&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewssynairgen-aerosolised-ifn-beta-shows-efficacy-against-pneumonia UK-based respiratory drug discovery and development company, Synairgen has presented the positive data from its pre-clinical study investigating the effectiveness of aerosolised interferon beta (IFN-beta) against viral pneumonia. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460636 Tue, 29 Nov 2011 00:00:00 +0100 5460636 http://www.medworm.com/index.php?rid=5460635&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-accepts-amarin-new-drug-application-for-amr101 The US Food and Drug Administration (FDA) has accepted Amarin's new drug application for AMR101 (icosapent ethyl), a drug to treat patients with very high triglycerides. (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5460635 Tue, 29 Nov 2011 00:00:00 +0100 5460635 http://www.medworm.com/index.php?rid=5451058&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewssummit-smt-c1100-secures-fda-orphan-drug-status UK-based drug discovery company Summit has received the US Food & Drug Administration's (FDA) orphan drug status for SMT C1100, used to treat Duchenne muscular dystrophy.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5451058 Mon, 28 Nov 2011 19:03:58 +0100 5451058 http://www.medworm.com/index.php?rid=5451057&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fcontractors%2Fgenomics%2Ftissue-solutions%2Fpresssample-availability-notifications.html Tissue Solutions is pleased to announce a new email-based service designed to notify researchers of the availability of fresh human samples.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5451057 Mon, 28 Nov 2011 19:03:58 +0100 5451057 http://www.medworm.com/index.php?rid=5451056&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-approves-intermezzo-sublingual-tablet-for-insomnia The US Food and Drug Administration (FDA) has approved Transcept Pharmaceuticals' Intermezzo (zolpidem tartrate) C-IV, used to treat insomnia.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5451056 Mon, 28 Nov 2011 19:03:58 +0100 5451056 http://www.medworm.com/index.php?rid=5443689&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-grants-clearance-for-tonix-to-begin-tnx-102-study Tonix Pharmaceuticals has received US Food Drug and Administration (FDA) approval to initiate a comparative pharmacokinetic and bioavailability study of TNX-102, an oral formulation of cyclobenzaprine for the treatment of fibromyalgia.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443689 Fri, 25 Nov 2011 18:44:03 +0100 5443689 http://www.medworm.com/index.php?rid=5443688&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsregeneron-eylea-injection-wins-fda-nod The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Eylea (aflibercept) injection for the treatment of patients with neovascular (wet) age-related macular degeneration.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443688 Fri, 25 Nov 2011 18:44:03 +0100 5443688 http://www.medworm.com/index.php?rid=5443687&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewscelldex-presents-survival-data-from-glioblastoma-drug-trial Celldex Therapeutics has presented mature overall survival data from a Phase II trial of rindopepimut (CDX-110) in patients with EGFRvIII-positive glioblastoma.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443687 Fri, 25 Nov 2011 18:44:03 +0100 5443687 http://www.medworm.com/index.php?rid=5443686&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsportola-secures-financing-for-phase-iii-betrixaban-study Portola Pharmaceuticals has secured $89m in preferred stock financing to advance its Phase III clinical programme of betrixaban, a once-daily, oral Factor Xa inhibitor.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443686 Fri, 25 Nov 2011 18:44:03 +0100 5443686 http://www.medworm.com/index.php?rid=5443685&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsprana-cleared-to-commence-alzheimers-drug-trial The Austin Health Research Ethics Committee has granted approval to Prana Biotechnology to initiate a 12-month Phase II Imaging trial in Australia to evaluate PBT2, an Alzheimer's drug.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443685 Fri, 25 Nov 2011 18:44:03 +0100 5443685 http://www.medworm.com/index.php?rid=5443684&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspfizer-to-buy-excaliard-pharmaceuticals Pfizer has entered into a definitive agreement to acquire Excaliard Pharmaceuticals, gaining access to EXC 001, a skin scarring treatment.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5443684 Fri, 25 Nov 2011 18:44:03 +0100 5443684 http://www.medworm.com/index.php?rid=5433631&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Flodotra--treatment-for-rheumatoid-arthritis%2F LODOTRA was developed utilising SkyePharma's proprietary GeoClock and GeoMatrix technologies, for which Horizon Pharma holds an exclusive worldwide license.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433631 Tue, 22 Nov 2011 18:42:22 +0100 5433631 http://www.medworm.com/index.php?rid=5433630&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturetaking-aim-with-nanotechnology%2F One of the key challenges of drug delivery is ensuring the right dose reaches the target without damaging healthy cells. Richard Moore of the Institute of Nanotechnology and inventor, entrepreneur and former MIT researcher Geoffrey von Maltzahn tell …Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433630 Tue, 22 Nov 2011 18:42:22 +0100 5433630 http://www.medworm.com/index.php?rid=5433629&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewspalifosfamide-combination-therapy-found-effective-against-sclc Ziopharm Oncology's intravenous Zymafos (palifosfamide or ZIO-201) has demonstrated promising clinical results in an ongoing Phase Ib open-label dose escalation study in patients with small cell lung cancer, and other selected cancers, when administe…Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433629 Tue, 22 Nov 2011 18:42:22 +0100 5433629 http://www.medworm.com/index.php?rid=5433628&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsgilead-tibotec-to-develop-hiv-medication Gilead Sciences has entered into a licence agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Emtriva (emtricitabine, GS7340) and cobicistat, a pharmacoenhancer.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433628 Tue, 22 Nov 2011 18:42:22 +0100 5433628 http://www.medworm.com/index.php?rid=5433627&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturetake-a-load-off-the-age-of-cloud-computing%2F Excessive, unmanageable data may be to blame for low productivity rates in the drug industry. Sarah Blackman looks at how cloud computing can streamline this data to make information more accessible and provide services that speed up and cut the cost…Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433627 Tue, 22 Nov 2011 18:42:22 +0100 5433627 http://www.medworm.com/index.php?rid=5433626&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsreport-highlights-rising-use-of-mental-health-medications-in-us A report from Medco Health Solutions revealed that more than one in five adult Americans took at least one medication to treat a psychiatric or behavioural disorder in 2010.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433626 Tue, 22 Nov 2011 18:42:22 +0100 5433626 http://www.medworm.com/index.php?rid=5433625&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsvirtify-adds-kallik-technology-to-labelling-solution Software developer Virtify has integrated Kallik's Automated Artwork Generation technology to its labelling solution for pharmaceutical and life science companies.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433625 Tue, 22 Nov 2011 18:42:22 +0100 5433625 http://www.medworm.com/index.php?rid=5433624&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsimprime-pgg-combination-therapy-found-effective-against-cancer Biothera's Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433624 Tue, 22 Nov 2011 18:42:22 +0100 5433624 http://www.medworm.com/index.php?rid=5433623&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fbanzel-treatment-for-linnaux-gastaut-syndrome%2F Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433623 Tue, 22 Nov 2011 18:42:22 +0100 5433623 http://www.medworm.com/index.php?rid=5433622&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-accepts-nda-filing-for-chelsea-northera-drug Chelsea Therapeutics has received US Food and Drug Administration (FDA) acceptance for the filing of a new drug application for Northera (droxidopa), designed to treat symptomatic neurogenic orthostatic hypotension.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5433622 Tue, 22 Nov 2011 18:42:22 +0100 5433622 http://www.medworm.com/index.php?rid=5424354&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewslallemand-and-gm-pharmaceuticals-launch-ismigen-in-georgia Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5424354 Sat, 19 Nov 2011 18:53:02 +0100 5424354 http://www.medworm.com/index.php?rid=5411825&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsalkermes-vivitrol-treats-opioid-dependence-in-study Alkermes' Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid deto…Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411825 Thu, 17 Nov 2011 09:25:21 +0100 5411825 http://www.medworm.com/index.php?rid=5411824&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsanacor-completes-patient-enrollment-for-an2690-drug-study Anacor Pharmaceuticals has concluded patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411824 Thu, 17 Nov 2011 09:25:21 +0100 5411824 http://www.medworm.com/index.php?rid=5411823&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-grants-orphan-drug-status-to-santen-sirolimus-drug The US Food and Drug Administration (FDA) has issued orphan drug status for Santen's sirolimus (DE-109, rapamycin) drug as a treatment for chronic / refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuv…Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411823 Thu, 17 Nov 2011 09:25:21 +0100 5411823 http://www.medworm.com/index.php?rid=5411822&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbaxter-international-acquires-baxa Baxter International has acquired Baxa, the US-based developer of pharmacy technology, for a cash consideration of $380m.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411822 Thu, 17 Nov 2011 09:25:21 +0100 5411822 http://www.medworm.com/index.php?rid=5411821&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Ffeatures%2Ffeaturepharma-technology-focus-issue-7%2F Finding new cures: This month we look at trends and progress in drug discovery and development.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411821 Thu, 17 Nov 2011 09:25:21 +0100 5411821 http://www.medworm.com/index.php?rid=5411820&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsbristol-myers-squibb-and-pfizer-report-apixaban-trial-results Bristol-Myers Squibb and Pfizer have presented the results of the Phase III trial to compare apixaban (Eliquis) to enoxaparin in acutely ill medical patients.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411820 Thu, 17 Nov 2011 09:25:21 +0100 5411820 http://www.medworm.com/index.php?rid=5411819&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-approves-intelgenx-anti-depressant The US Food and Drug Administration (FDA) has approved IntelGenxs' anti-depressant CPI-300 to treat patients with major depressive disorder.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411819 Thu, 17 Nov 2011 09:25:21 +0100 5411819 http://www.medworm.com/index.php?rid=5411818&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewslallemand-and-gm-pharmaceuticals-launch-ismigen-in-georgia Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411818 Thu, 17 Nov 2011 09:25:21 +0100 5411818 http://www.medworm.com/index.php?rid=5411817&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsfda-accepts-neurogesx-supplemental-new-drug-application-for-qutenza The US Food and Drug Administration (FDA) is set to review NeurogesX's supplemental new drug application for Qutenza (capsaicin) 8% patch as a treatment for neuropathic pain associated with HIV-associated peripheral neuropathy.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5411817 Thu, 17 Nov 2011 09:25:21 +0100 5411817 http://www.medworm.com/index.php?rid=5402190&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsopexa-tovaxin-drug-receives-fda-fast-track-designation The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics' Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5402190 Sun, 13 Nov 2011 18:07:38 +0100 5402190 http://www.medworm.com/index.php?rid=5402189&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewssalix-to-acquire-oceana-operating-subsidiary Oceana Therapeutics has signed a definitive agreement for the sale of its operating subsidiary to Salix Pharmaceuticals for $300m.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5402189 Sun, 13 Nov 2011 18:07:38 +0100 5402189 http://www.medworm.com/index.php?rid=5402188&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fdownloads%2Fwhitepapers%2Fresearch%2Ffileprocess-models%2F While process understanding can come from a variety of sources, scaled down process models of unit operations have particular utility.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5402188 Sun, 13 Nov 2011 18:07:38 +0100 5402188 http://www.medworm.com/index.php?rid=5391305&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fprojects%2Fpirfenidone-treatment-for-idiopathic-pulmonary-fibrosis%2F Pirfenidone is a drug indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring and thickening of lungs.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5391305 Thu, 10 Nov 2011 19:36:22 +0100 5391305 http://www.medworm.com/index.php?rid=5391304&cid=s_22571_34_f&fid=22571&url=http%3A%2F%2Fwww.drugdevelopment-technology.com%2Fnews%2Fnewsexelixis-to-commence-prostate-cancer-drug-trial Exelixis has announced that it will begin the pivotal Phase III '306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.Post to:Delicious  Digg  reddit  Facebook  StumbleUpon   (Source: Drug Development Technology) Drug Development Technology news http://www.medworm.com/rss/comments.php?id=5391304 Thu, 10 Nov 2011 19:36:22 +0100 5391304